ArticleBMC cancer2025
Nomogram based on the advanced lung cancer inflammation index and other relevant clinical factors for patients with cervical squamous cell carcinoma undergoing concurrent chemoradiotherapy.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND AND
objectiveThis study aims to explore the association between the advanced lung cancer inflammation index (ALI), the adjusted Charlson Comorbidity Index (ACCI), and other relevant clinical factors and the prognosis of patients with cervical squamous cell carcinoma (CSCC) who undergoing concurrent chemoradiotherapy, and to construct a corresponding prognostic model.
methodsA total of 243 patients with CSCC who undergoing concurrent chemoradiotherapy between January 2017 and December 2023 were included in this study. Univariate and multivariate Cox regression analyses were conducted to identify independent prognostic factors influencing progression-free survival (PFS) and overall survival (OS). These independent prognostic factors were subsequently utilized to construct two nomograms, which were then subjected to a comprehensive series of validations. Ultimately, a risk stratification framework was developed to evaluate the prognostic outcomes of patients across varying risk categories.
resultsALI, ACCI, American Joint Committee on Cancer (AJCC) stage, and tumor volume were identified as independent predictors of PFS and OS (all P < 0.05). Based on these independent clinical factors, we developed two distinct nomograms for the prediction of progression-free survival (PFS) and overall survival (OS), respectively. In the training cohort, the C-indexes of the model for PFS and OS were 0.743 and 0.741, respectively; while the corresponding C-indexes were 0.735 and 0.728 in the validation cohort. Following an extensive series of validations, the newly developed nomogram models demonstrated superior performance compared to the traditional AJCC staging system. Based on the total risk points derived from the nomograms, we stratified all patients into three risk subgroups: high-risk, medium-risk, and low-risk. Patients in three distinct risk subgroups exhibited significantly different survival outcomes.
conclusionALI has significant value for predicting PFS and OS of CSCC patients who have undergone concurrent chemoradiotherapy. The newly developed nomogram models based on ALI demonstrates robust performance and offers a valuable reference for personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.